FDA moves to fast-track 3 psychedelic drugs for review
Digest more
After an executive order, the FDA announced it would prioritize the study of some psychedelic drugs for therapeutic use. Which did they choose and why?
FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may obviate a second Phase 3 study in rare diseases. Methodological standards for RWD are tightening,
New legislation introduced by a bipartisan group of US senators would make it more difficult for new and generic opioid drugs to obtain the approval of the US Food and Drug Administration (FDA). The bill, the FDA Accountability for Public Safety Act (FAPSA ...
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.